Physitrack Limited (PTRK) AI Stock Analysis

• Market Cap: kr291.88M
• Dividend Yield: N/A
• Average Volume (3M): 95.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: -5.40%
• EPS Growth: -320.49%
• Country: SE
• Employees: 81
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.00
• Shares Outstanding: 16,260,765
• 10 Day Avg. Volume: 45,396
• 30 Day Avg. Volume: 95,304
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr17.50
• Price Target Upside: -2.78% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 54 Neutral
• Price Target: kr17.50 ▼(-2.78% Downside)

The overall stock score is primarily impacted by significant financial challenges, including declining revenue growth and negative profitability margins. Despite these issues, the stock shows positive technical momentum, which partially offsets the financial weaknesses. However, the negative P/E ratio and lack of dividend yield present valuation concerns.

Physitrack Limited Business Overview & Revenue Model

Company Description

Physitrack Limited (PTRK) is a technology company operating in the digital health sector, offering innovative solutions for physical therapy and rehabilitation. The company provides a cloud-based platform that enables healthcare professionals to create and deliver personalized exercise programs, monitor patient progress, and facilitate telehealth consultations. Physitrack's core products include exercise prescription software and telehealth services, which are widely used by physiotherapists, clinics, and hospitals globally to enhance patient care and improve healthcare outcomes.

How the Company Makes Money

Physitrack Limited generates revenue primarily through subscription-based services offered to healthcare professionals and institutions. The company charges a recurring fee for access to its comprehensive exercise prescription and telehealth platform. Key revenue streams include individual practitioner subscriptions, multi-user licenses for clinics and hospitals, and enterprise solutions for larger healthcare organizations. Additionally, Physitrack may partner with health insurance companies or other healthcare providers to integrate its platform into broader healthcare ecosystems, potentially leading to additional revenue opportunities through value-added services and collaborations.

Physitrack Limited Financial Statement Overview

Summary

Physitrack Limited faces significant financial challenges, with declining revenue growth and negative profitability margins. While the balance sheet shows low leverage, the negative return on equity and cash flow issues indicate operational and financial inefficiencies.

Income Statement

Physitrack Limited shows a declining revenue growth rate of -2.83% in the TTM period, indicating challenges in maintaining revenue momentum. The company has negative net profit and EBIT margins, reflecting ongoing profitability issues. Despite a strong gross profit margin of 59.85% in the TTM, the negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio of 0.22 in the TTM suggests a conservative leverage approach, which is a positive indicator of financial stability. However, the negative return on equity of -30.77% indicates that the company is not generating sufficient returns on shareholders' equity, which is a concern for investors.

Cash Flow

Physitrack Limited's free cash flow growth rate is significantly negative at -343.69% in the TTM, indicating cash flow challenges. The operating cash flow to net income ratio of 0.63 suggests that the company is generating cash flow, but the negative free cash flow to net income ratio highlights issues in translating earnings into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.18M	16.18M	15.18M	12.51M	7.81M	5.83M
Gross Profit	11.97M	16.18M	3.87M	12.37M	7.81M	5.83M
EBITDA	-2.23M	-2.09M	7.09M	2.57M	1.07M	1.60M
Net Income	-6.47M	-6.45M	3.20M	92.32K	-815.03K	688.41K
Balance Sheet
Total Assets	27.69M	30.51M	38.70M	41.31M	32.28M	11.95M
Cash, Cash Equivalents and Short-Term Investments	467.53K	723.39K	536.03K	577.74K	13.32M	775.55K
Total Debt	4.27M	4.81M	3.58M	831.66K	1.31K	1.97M
Total Liabilities	9.37M	11.34M	13.13M	18.94M	3.63M	6.76M
Stockholders Equity	18.32M	19.17M	25.57M	22.37M	23.29M	5.19M
Cash Flow
Free Cash Flow	598.04K	-363.54K	-773.78K	-3.04M	654.05K	1.05M
Operating Cash Flow	3.66M	3.13M	2.65M	1.45M	659.81K	2.03M
Investing Cash Flow	-3.09M	-3.49M	-5.04M	-14.78M	-4.54M	-773.58K
Financing Cash Flow	-670.57K	537.79K	2.34M	795.50K	14.85M	-3.37K

Physitrack Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PTRK, the sentiment is Positive. The current price of 18 is below the 20-day moving average (MA) of 19.21, above the 50-day MA of 17.33, and above the 200-day MA of 12.92, indicating a neutral trend. The MACD of 0.26 indicates Positive momentum. The RSI at 46.29 is Neutral, neither overbought nor oversold. The STOCH value of 9.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:PTRK.

Physitrack Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PTRK	54 Neutral	kr291.88M	―		―	-5.40%	-320.49%
KONT	46 Neutral	70.33M	-42.09	-3.37%	―	-1.24%	-168.20%
QLINEA	41 Neutral	180.20M	-0.20	-145.65%	―	16.98%	36.29%
ISOFOL	36 Underperform	226.29M	-2.72	0.00%	―	0.00%	-56.68%
ACTI	32 Underperform	204.45M	-3.68	0.00%	―	0.00%	27.61%
AINO	29 Underperform	49.51M	-7.76	0.00%	―	9.87%	67.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%